Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company successfully completed its strategic reorganization process and announced new program innovations.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
